Key result
Antihypertensive therapy cuts MACE ~20% per 10 mmHg drop in hypertensive diabetics.
Why the study?
Antihypertensive therapy in diabetic patients requires careful consideration because medications may alter macro- and microvascular complications and offer varying cardio- and reno-protective effects alongside blood pressure reduction.
Effect estimate: 20% reduction in major cardiovascular events per 10 mmHg BP reduction; 35% reduction in heart failure; 32% mortality reduction in UKPDS-38; 9% reduction major macro/microvascular events in ADVANCE BP
This review emphasizes that while blood pressure reduction is critical in diabetic patients, the choice of antihypertensive medication must be personalized to optimize cardiovascular, renal, and metabolic outcomes.
Affirms BP-lowering benefits in diabetic hypertension; leaves open optimal agent selection for renal and metabolic outcomes.
Treating hypertension in diabetic patients with antihypertensive medications should be done with careful consideration because these medications may interfere with macro- and microvascular complications of diabetes, such as myocardial infarction, stroke, and diabetic nephropathy. Some medications also come with cardio- and reno-protective effects along with lowering blood pressure. This narrative review focuses on major antihypertensive drug classes and their efficacy, safety, and metabolic impacts in type 1 and type 2 diabetes mellitus. We found that most classes of drugs, such as ACEIs (Angiotensin-Converting Enzyme Inhibitors), ARBs (Angiotensin II-Receptor Blockers), and thiazide diuretics, exert cardio- and renoprotective effects but also come with their own set of side effects, including dry cough, hyperkalemia, and hypokalemia, respectively. Beta blockers are used when patients have underlying conditions such as a previous heart attack or angina, but with caution, as they can cause masking of hypoglycemia. This review also discusses emerging therapies such as SGLT2 (Sodium-Glucose CoTransporter-2) inhibitors. Hence, all these drugs can offer additional benefits in addition to lowering blood pressure if chosen properly and tailored to suit the patient’s overall health needs.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2026) conducted a review in Hypertension with Type 1 or Type 2 Diabetes Mellitus. Antihypertensive therapy reduces major cardiovascular events by 20% per 10 mmHg BP reduction, heart failure by 35%, and mortality by up to 32% in diabetics with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: